SILVER SPRING, Md. - An FDA advisory panel provided late-stage lung cancer patients with a ray of hope Tuesday when it leaned toward recommending approval of Iressa, an epidermal growth factor receptor tyrosine kinase inhibitor. (BioWorld Today)